Positive news carried by the University of Oxford to the British and the world by announcing that the vaccine that we are developing against the Corona virus, has shown its effectiveness in facing the virus and its ability to give immunity to the body against this disease, which makes this vaccine tops the vaccines close to dependence on a long list of vaccines that It is being developed in different countries.
Perhaps the British government's wager on this vaccine appeared months ago when Prime Minister Boris Johnson announced the allocation of more than 20 million pounds to support the British University project, and to accelerate all stages of research and testing.
The entry of the British pharmaceutical giant AstraZeneca online to contribute to the development of the vaccine gave a strong boost to the work of developing the vaccine, which means that if the vaccine gets approval, it will be possible to produce it in large quantities.
After the results of the vaccine selection were published to a thousand people in the famous scientific journal "Lancet", which shows that the vaccine is effective and safe, the Oxford University vaccine has become perhaps "the world's hope" for its imminent use.
The challenge raised by the British Minister of Health Matt Hancon last April, when he responded to the criticism directed at the British government as slow to raise the number of examinations compared to Germany, was not disappointed, at which time the minister recognized Germany's strength in the field of medical equipment manufacturing, but he stressed that Britain It is the leader in scientific and medical research, which is confirmed by the evolution of the Oxford University vaccine compared to other vaccines.
Vaccine race
Despite the positive results shown by the University of Oxford vaccine, the British government announced the conclusion of a deal to purchase 90 million doses of potential vaccines for the Corona virus, with the aim of securing workers in the first line to counter the virus.
And on the details of this deal, Minister of Commerce Alok Sharma announced that 90 million doses will be sufficient to secure health workers first, and workers in care homes where they will have priority, but the main goal of this deal - according to a number of observers - is that Britain guarantees itself a share From any vaccine that shows its effectiveness, it is expected that a conflict similar to the muzzle conflict will break out if any vaccine is approved to confront Corona.
And about the details of this deal, the government has contracted with the German company "Piontech", which develops a vaccine that succeeded in the first stage tests. The deal is based on the British government obtaining 30 million doses of this vaccine if it is approved. The German company announced that the results of the vaccine test It was positive in the first stage, awaiting the remaining stages.
The second vaccine is being developed by the French company Valvina, which is considered less advanced compared to the University of Oxford vaccine and the German "Piontech" vaccine. However, the government entered into a contract to obtain 60 million doses, and if the vaccine shows its efficacy and is safe for human use, The deal would give the British government additional 40 million doses.
As for the reason for the British government's investment in the vaccine of the French company, "Valvina", it is mainly due to the fact that the factory of this company is located in Scotland, and on this basis the government offered to finance the clinical trials of the vaccine, and in the event of its success and expansion of the factory in Scotland will lead to the creation of labor and economic movement Real in the area.
Britain first
and it appeared through the announcement of the British Minister of Commerce about this deal the main goal behind it, which is to secure Britain's share of the "vaccine cake", where he described what is currently happening as a hunt for the vaccine, and the British government aims to be among the lucky countries that First, you will get any effective vaccine, which for her may constitute a health, economic and even political success, especially in front of the many criticisms directed at the Johnson government and the way it deals with the Corona epidemic.
With this deal, Britain has secured its share of two vaccines that are produced outside its borders, in addition to the Oxford vaccine for which it concluded an agreement with the university to obtain 100 million doses from it, and British Prime Minister Boris Johnson agreed with US President Donald Trump a few weeks ago to coordinate and benefit jointly. From any vaccine shows its efficacy first.
The British government moved to the top speed in research developing a vaccine against the Coronavirus, when the Minister of Health announced that it had opened the door to hundreds of thousands of volunteers to undergo potential vaccinations against the virus, declaring that they needed more than half a million volunteers, the largest number to be tested in the world.
What increases the possibility that Britain will become one of the first countries to benefit from a vaccine against the Corona virus, after the announcement by the Indian Foundation "Serum" - which is the largest vaccine manufacturer in the world - that it will not wait for the results of the vaccine test in humans, to start manufacturing millions of doses from The vaccine, until it is ready for promotion immediately after it gets approved, and Britain will be the first to obtain these vaccines from the Indian company.
Nevertheless, the language of cautious optimism still prevails among British officials, beginning with Prime Minister Boris Johnson, who had previously excluded the possibility of a vaccine against the Coronavirus before it changed its tone after the results of the Oxford vaccine tests were announced, and expressed the possibility of a vaccine with The end of the year or the beginning of next year, and Health Minister Matt Hancock stressed that more research is needed to ensure that the vaccine is completely safe for human use.